Canada Markets closed

Takeda Pharmaceutical Company Limited (TKPHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
29.420.00 (0.00%)
At close: 11:16AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close28.97
Bid0.00 x 0
Ask0.00 x 0
Day's Range28.97 - 28.97
52 Week Range26.03 - 34.68
Avg. Volume88,682
Market Cap45.896B
Beta (5Y Monthly)1.00
PE Ratio (TTM)11.30
EPS (TTM)2.60
Earnings DateN/A
Forward Dividend & Yield1.38 (4.88%)
Ex-Dividend DateSept 29, 2022
1y Target EstN/A
  • Business Wire

    Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

    CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash., May 26, 2022--Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association

  • Motley Fool

    Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

    On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.

  • Reuters

    Japan's Takeda forecasts rebound despite full-year profit drop

    Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.